Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Payables (2023 - 2025)

Historic Payables for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $4.8 million.

  • Applied Therapeutics' Payables rose 6919.28% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 6919.28%. This contributed to the annual value of $4.4 million for FY2024, which is 15447.76% up from last year.
  • Per Applied Therapeutics' latest filing, its Payables stood at $4.8 million for Q3 2025, which was up 6919.28% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Applied Therapeutics' Payables peaked at $6.0 million during Q3 2023, and registered a low of $1.7 million during Q4 2023.
  • Its 3-year average for Payables is $4.2 million, with a median of $4.7 million in 2023.
  • Over the last 5 years, Applied Therapeutics' Payables had its largest YoY gain of 15447.76% in 2024, and its largest YoY loss of 5275.6% in 2024.
  • Applied Therapeutics' Payables (Quarter) stood at $1.7 million in 2023, then skyrocketed by 154.48% to $4.4 million in 2024, then grew by 8.28% to $4.8 million in 2025.
  • Its Payables was $4.8 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.9 million in Q1 2025.